Operating Expenses

R&D

Vicor R&D increased by 8.5% to $22.29M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.0%, from $19.38M to $22.29M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 10.3% CAGR.

Analysis

StatementIncome Statement
SectionOperating Expenses
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 30, 2026

How to read this metric

Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.

Detailed definition

Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...

Peer comparison

Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.

Metric ID: research_and_development

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$13.27M$13.52M$13.30M$14.25M$15.52M$14.75M$16.08M$15.87M$16.94M$17.75M$17.30M$18.04M$16.94M$16.96M$16.98M$19.38M$18.79M$19.86M$20.54M$22.29M
QoQ Change+1.9%-1.6%+7.2%+8.9%-5.0%+9.0%-1.3%+6.7%+4.8%-2.5%+4.3%-6.1%+0.1%+0.1%+14.1%-3.0%+5.7%+3.4%+8.5%
YoY Change+16.9%+9.1%+20.9%+11.3%+9.1%+20.4%+7.6%+13.7%+0.0%-4.5%-1.8%+7.4%+10.9%+17.1%+21.0%+15.0%
Range$13.27M$22.29M
CAGR+11.5%
Avg YoY Growth+10.9%
Median YoY Growth+11.1%
Current Streak3 quarters growth

Frequently Asked Questions

What is Vicor's r&d?
Vicor (VICR) reported r&d of $22.29M in Q1 2026.
How has Vicor's r&d changed year-over-year?
Vicor's r&d increased by 15.0% year-over-year, from $19.38M to $22.29M.
What is the long-term trend for Vicor's r&d?
Over 4 years (2021 to 2025), Vicor's r&d has grown at a 10.3% compound annual growth rate (CAGR), from $53.11M to $78.57M.
What does r&d mean?
The money spent on creating new products or improving existing ones to drive future growth.